tirzepatide cvot results and cardiometabolic parameters in obesity: Summary of current evidence - Sattar - 2025 - Diabetes, Obesity and Metabolism AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide

A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism

That gap, about 3 to 4 percentage points, is statistically meaningful but requires context to interpret properly

These factors have particularly impacted individuals with lower health literacy, food/nutrition literacy, and socioeconomic statusperpetuating health inequities for dietrelated diseases [256, 259]

N.RushovichT.GompersA.BoulicaultM.WorthingtonS.LockhartJ

Nicholls SJ, Bhatt DL, Buse JB et al (2024) Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics